For Immediate Release
Chicago, IL – July 10, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Stryker Corp. (SYK), Zimmer Holdings (ZMH), Conmed (CNMD), Smith & Nephew (SNN) and Wright Medical (WMGI).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday’s Analyst Blog:
Stryker Strikes Advanced Medical Deal
Stryker Corp. (SYK) recently signed a deal for global marketing and distribution rights of Advanced Medical Solutions Group Plc’s LiquiBand wound closure products that are used in cranio-maxillofacial (CMF) surgeries.
LiquiBand is a tissue adhesive used to close minor surgical wounds and trauma. The product would be launched in European markets this month and would be followed by a phased roll out in the rest of the world.
The deal is going to be a win-win for both the companies. Stryker will earn commissions that will take care of the company’s bottom-line during these testing times of global recession. Advanced Medical can leverage Stryker’s global presence and its brand equity.
Stryker is one of the world’s largest medical devices companies operating in the global orthopedic market. The company currently has two segments: Orthopedic Implant and MedSurg Equipment. The Orthopedic Implant segment includes hip, knee, shoulder and spinal implants and associated instruments; trauma-related products; bone cement; and Stryker Leibingers (plate and screw systems for hand, face, and head procedures). The MedSurg Equipment segment is comprised of three main divisions: Stryker Instruments (powered surgical tools), Stryker Endoscopy (powered surgical instruments and viewing aids) and Stryker Medical (specialty stretchers).
Stryker faces competition from major players like Zimmer Holdings (ZMH), Conmed (CNMD), Smith & Nephew (SNN) and Wright Medical (WMGI).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/ZacksInvestment
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
